Nurix Therapeutics Stock Target Price
| NRIX Stock | USD 11.27 0.11 0.99% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Nurix Therapeutics' long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Nurix Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nurix Therapeutics' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nurix Therapeutics could also be used in its relative valuation, which is a method of valuing Nurix Therapeutics by comparing valuation metrics of similar companies.Nurix Therapeutics is currently under evaluation in target price category among its peers.
Nurix Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (3.41) % | ||||
| Current Valuation | 327.73 M | ||||
| Shares Outstanding | 76.24 M | ||||
| Shares Owned By Insiders | 1.39 % | ||||
| Shares Owned By Institutions | 98.61 % | ||||
| Number Of Shares Shorted | 14.39 M | ||||
| Price To Book | 1.77 X | ||||
| Price To Sales | 15.23 X | ||||
| Revenue | 54.55 M | ||||
| Gross Profit | (184.87 M) | ||||
| EBITDA | (196.6 M) | ||||
| Net Income | (193.57 M) | ||||
| Cash And Equivalents | 344.48 M | ||||
| Cash Per Share | 7.31 X | ||||
| Total Debt | 28.3 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 5.26 X | ||||
| Book Value Per Share | 6.31 X | ||||
| Cash Flow From Operations | (172.58 M) | ||||
| Short Ratio | 12.00 X | ||||
| Earnings Per Share | (2.79) X | ||||
| Target Price | 30.0 | ||||
| Number Of Employees | 286 | ||||
| Beta | 2.24 | ||||
| Market Capitalization | 859.18 M | ||||
| Total Asset | 669.34 M | ||||
| Retained Earnings | (738.77 M) | ||||
| Working Capital | 523.53 M | ||||
| Net Asset | 669.34 M |
About Nurix Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nurix Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nurix Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nurix Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.